Tvardi Therapeutics, Inc. Common Stock TVRD

$1.86 -2.11% at last close

Analyst Consensus

Consensus Rating
Moderate Buy (3 Buy · 1 Hold · 1 Sell)
Average Price Target
$6.00
Implied Upside
+222.6%
Price Target Range
$3.00 – $10.00
Analysts (12 mo)
5

Recent Analyst Actions

DateFirmActionRatingPrice Target
2026-07-30
BTIGJulian Harrison
 Maintains Buy $15 → $5
2026-07-08
Raymond JamesRyan Deschner
 Upgrades Market perform → Outperform $10
2026-07-07
BTIGJulian Harrison
 Reiterates Buy $15
2026-06-08
HC Wainwright & Co.Sara Nik
 Initiates coverage on Buy $9
2026-04-20
BarclaysEtzer Darout
 Downgrades Equal-weight → Underweight $4 → $3
2026-04-01
BTIGJulian Harrison
 Reiterates Buy $15
2026-04-01
BarclaysEtzer Darout
 Maintains Equal-weight $5 → $4
2026-04-01
Piper SandlerYasmeen Rahimi
 Maintains Neutral $4 → $3
2025-10-14
Raymond JamesRyan Deschner
 Downgrades Outperform → Market perform —
2025-10-13
BTIGJulian Harrison
 Maintains Buy $55 → $15
2025-10-13
BarclaysEtzer Darout
 Initiates coverage on Overweight $61
2025-07-14
Raymond JamesRyan Deschner
 Initiates coverage on Outperform $62
2025-07-11
Cantor FitzgeraldSteve Seedhouse
 Initiates coverage on Overweight $52
2025-06-12
Piper SandlerYasmeen Rahimi
 Initiates coverage on Overweight $78
2025-05-21
OppenheimerJay Olson
 Initiates coverage on Outperform $65
2025-04-28
Jones TradingDebanjana Chatterjee
 Initiates coverage on Buy $39

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$1.86
Market Cap
$25.34 million
52-Week Range
$1.50 – $43.65
Average Volume
4.59 million shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.